These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 8521882)
21. Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. Nodari S; Metra M; Dei Cas A; Dei Cas L Eur J Heart Fail; 2003 Dec; 5(6):803-9. PubMed ID: 14675859 [TBL] [Abstract][Full Text] [Related]
23. Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol. Jourdain P; Funck F; Fulla Y; Hagege A; Bellorini M; Guillard N; Loiret J; Thebault B; Desnos M Eur J Heart Fail; 2002 Jun; 4(3):269-76. PubMed ID: 12034151 [TBL] [Abstract][Full Text] [Related]
24. Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. McTavish D; Campoli-Richards D; Sorkin EM Drugs; 1993 Feb; 45(2):232-58. PubMed ID: 7681374 [TBL] [Abstract][Full Text] [Related]
25. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Cleland JG; Pennell DJ; Ray SG; Coats AJ; Macfarlane PW; Murray GD; Mule JD; Vered Z; Lahiri A; Lancet; 2003 Jul; 362(9377):14-21. PubMed ID: 12853194 [TBL] [Abstract][Full Text] [Related]
26. The carvedilol hibernation reversible ischaemia trial, marker of success (CHRISTMAS) study. Methodology of a randomised, placebo controlled, multicentre study of carvedilol in hibernation and heart failure. Pennell DJ; Ray SG; Davies G; Burgess M; Webster J; Slomka P; Atkinson P; Cleland JG Int J Cardiol; 2000 Feb; 72(3):265-74. PubMed ID: 10716137 [TBL] [Abstract][Full Text] [Related]
27. [Acute hemodynamic effects of the vasodilator beta blocker carvedilol in heart failure]. Buchwald A; Unterberg C; van der Does R; Wiegand V Z Kardiol; 1990 Jun; 79(6):424-8. PubMed ID: 1974100 [TBL] [Abstract][Full Text] [Related]
28. Carvedilol in heart failure. Kelly DT Cardiology; 1993; 82 Suppl 3():45-9. PubMed ID: 8106165 [TBL] [Abstract][Full Text] [Related]
29. Effects of carvedilol on ventriculo-arterial coupling in patients with heart failure. Razzolini R; Tarantini G; Boffa GM; Orlando S; Iliceto S Ital Heart J; 2004 Jul; 5(7):517-22. PubMed ID: 15487269 [TBL] [Abstract][Full Text] [Related]
30. Carvedilol: a review of its use in chronic heart failure. Keating GM; Jarvis B Drugs; 2003; 63(16):1697-741. PubMed ID: 12904089 [TBL] [Abstract][Full Text] [Related]
31. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Takeda Y; Fukutomi T; Suzuki S; Yamamoto K; Ogata M; Kondo H; Sugiura M; Shigeyama J; Itoh M Am J Cardiol; 2004 Aug; 94(4):448-53. PubMed ID: 15325927 [TBL] [Abstract][Full Text] [Related]
32. Can intravenous beta blockade predict long-term haemodynamic benefit in chronic congestive heart failure secondary to ischaemic heart disease? A comparison between intravenous and oral carvedilol. DasGupta P; Lahiri A Clin Investig; 1992; 70 Suppl 1():S98-104. PubMed ID: 1350492 [TBL] [Abstract][Full Text] [Related]
33. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy. Tatli E; Kurum T Can J Cardiol; 2005 Mar; 21(4):344-8. PubMed ID: 15838561 [TBL] [Abstract][Full Text] [Related]
34. Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Dunn CJ; Lea AP; Wagstaff AJ Drugs; 1997 Jul; 54(1):161-85. PubMed ID: 9211087 [TBL] [Abstract][Full Text] [Related]
35. Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction. Frishman WH; Henderson LS; Lukas MA Vasc Health Risk Manag; 2008; 4(6):1387-400. PubMed ID: 19337551 [TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. Cohn JN; Fowler MB; Bristow MR; Colucci WS; Gilbert EM; Kinhal V; Krueger SK; Lejemtel T; Narahara KA; Packer M; Young ST; Holcslaw TL; Lukas MA J Card Fail; 1997 Sep; 3(3):173-9. PubMed ID: 9330125 [TBL] [Abstract][Full Text] [Related]
37. Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials. Fung JW; Chan SK; Yeung LY; Sanderson JE Eur J Heart Fail; 2002 Aug; 4(4):489-94. PubMed ID: 12167389 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of a new vasodilating beta-blocking agent, carvedilol, in exertional angina using holter monitoring. Kishida H; Saito T; Fukuma N; Hata N; Suzuki T; Ohtsu F Jpn Heart J; 1990 Jul; 31(4):449-60. PubMed ID: 1977939 [TBL] [Abstract][Full Text] [Related]
39. Carvedilol in the failing heart. Lombardi WL; Gilbert EM Clin Cardiol; 2001 Dec; 24(12):757-66. PubMed ID: 11768738 [TBL] [Abstract][Full Text] [Related]
40. Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Metra M; Covolo L; Pezzali N; ZacĂ V; Bugatti S; Lombardi C; Bettari L; Romeo A; Gelatti U; Giubbini R; Donato F; Dei Cas L Cardiovasc Drugs Ther; 2010 Feb; 24(1):49-60. PubMed ID: 20352314 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]